1FDA. Questions and Answers: FDA Recommends Against the Continued Use of Meridia (sibutramine) [EB/OL]. [2010-10-08].http:// www. fda. gov/Drugs/DrugSafety/ucmZ28747, htm.
3FDA. Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride) [ EB/OL] . [2010 - 02 - 22 ] , http : / / www. fda. gov/Drugs/DrugSafety/Postmarket Drug Safety Information for Patientsand Providers/Drug Safety Information for Heathcare Profession- als/ueml91650, htm.
4FDA. Follow - Up to the November 2009 Early Comnlunication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia[EB/OL]. [ 2010 - 01 - 21 ] . http : / / www. fda. gov / Drugs / DrugSafety / Postmarket Drug Safety Information for Patientsand Providers/Drug Safety Information for I-Ieathcare Prufessionals/ucm198206. htm.
5FDA. FDA Drug Safety Communication: FDA Recommends Agaitlst the Continued Use of Meridia (sibutramine) [EB/OL] . [2010- 10-081. http : //www. fda. gov/Drugs/Drug Safety/ucm228746. htm.
